The VAD chemotherapy regimen plus a G-CSF dose of 10 microg/kg is as effective and less toxic than high-dose cyclophosphamide plus a G-CSF dose of 5 microg/kg for progenitor cell mobilization: results from a monocentric study of 82 patients

Bone Marrow Transplantation
F LefrèreB Varet

Abstract

A study was conducted to compare the efficiency and toxicity of two peripheral blood stem cell (PBSC) mobilization procedures for newly diagnosed patients with multiple myeloma. Patients from group 1 (n=51) were treated by high-dose cyclophosphamide (HD-CY) plus G-CSF (5 microg/kg/day), and the second group (n=31) by VAD regimen plus G-CSF administration (10 microg/kg/day). Successful mobilization, defined by a minimal count of 2.5 x 10(6) CD34(+) cells/kg collected, was achieved in 96 and 90% of patients in groups 1 and 2, respectively (P=0.15). The mean peripheral blood CD34(+) cells concentration and the mean CD34(+) cells/kg collected were higher in group 2 than in the group 1 (P=0.05). The mean number of leukaphereses necessary to collect a count of 2.5 x 10(6) CD34(+) cells/kg was reduced in group 2 compared to group 1. Adverse events, blood products consumption and time spent in the hospital were significantly greater after HD-CY. In conclusion, VAD plus a G-CSF dose of 10 microg/kg administration seems preferential to HD-CY plus a G-CSF dose of 5 microg/kg for PBSC collection because of equivalent or better efficiency in stem cell mobilization, strong favorable toxicity profile and reduced cost.

References

May 24, 1984·The New England Journal of Medicine·B BarlogieR Alexanian
Apr 29, 1998·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·K R DesikanG Tricot
Dec 26, 2003·The New England Journal of Medicine·Michel AttalUNKNOWN InterGroupe Francophone du Myélome

❮ Previous
Next ❯

Citations

Dec 18, 2013·Transfusion and Apheresis Science : Official Journal of the World Apheresis Association : Official Journal of the European Society for Haemapheresis·Sibel HacıoğluAli Keskin
Feb 2, 2016·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Christopher ParrishUNKNOWN National Cancer Research Institute Haemato-Oncology Clinical Studies Group
Feb 14, 2012·Clinics in Geriatric Medicine·Anthony MatoAndre Goy
Jan 10, 2008·European Journal of Haematology·Esa Jantunen, Taru Kuittinen
Oct 22, 2013·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Sergio GiraltSteven Devine
Sep 8, 2004·Food and Chemical Toxicology : an International Journal Published for the British Industrial Biological Research Association·Hao Jing, David D Kitts
Jul 20, 2010·British Journal of Haematology·Morie A Gertz

❮ Previous
Next ❯

Related Concepts

Related Feeds

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.